Sponsored

Content sponsored by Sanofi

A novel, mechanism-based approach that addresses the biologic drivers of this progressive disease

Looking Beyond the First Day: Building a Sustainable Hemophilia B Plan for School Years Ahead

Picture a patient in your practice who is in their late 60s and begins experiencing increasing fatigue, shortness of breath, and difficulty keeping up with the everyday activities they once handled with ease. For years, a patient may move from appointment to appointment searching for answers, and may be treated for heart failure, atrial fibrillation or simply told they are “getting older.”1 Their physicians believe that to be true. However, this patient may have transthyretin-mediated cardiac amyloidosis, or ATTR-CM. For many individuals living with ATTR-CM, the journey to understanding what is happening can be long, frustrating and emotionally exhausting, not only for themselves, but also for their families, caregivers, and healthcare professionals (HCPs) who are watching their overall health and well-being decline over time.

Timely and accurate Alzheimer’s disease (AD) diagnosis is critical for access to care planning, including potential treatment with disease-modifying therapies.

Carolyn S.P. Lam, MBBS, PhD, FRCP, is Senior Consultant Cardiologist at the National Heart Centre Singapore, and Professor at Duke-National University of Singapore Graduate Medical School Singapore, and Chief of Asia-Pacific Research & AI Innovation at Baim Institute.

Sponsored by Novartis Pharmaceuticals Corporation. Jason Liu, MD, was not compensated for his contributions to this article.

Content sponsored and created by Sanofi

Healthcare systems are navigating unprecedented demands, especially in rare disease, where existing resources often struggle to keep pace with real-time clinical needs and the ongoing shift toward value-based care. In this conversation, Duane Clark, General Manager, Rare Disease at Sanofi, and Robert Hopkin, MD, Clinical Geneticist at Cincinnati Children’s Hospital Medical Center, discuss how the field is changing and how the Sanofi 1RARE model has grown to help meet these changes.

Content sponsored and created by Sanofi